Gefitinib, Erlotinib or Afatinib for EGFR Mutated NSCLC patients? A Meta-Analysis and Indirect Comparison on the Efficacy of First-Line Tyrosine Kinase Inhibitors
作者
Marscha S. Holleman,Remziye Zaim,CA Uyl‐de Groot
出处
期刊:Value in Health [Elsevier BV] 日期:2016-11-01卷期号:19 (7): A714-A714